## **Core Concept**
HER2/neu, also known as ERBB2, is a gene that can play a role in the development of breast cancer. Overexpression of the HER2/neu protein occurs in approximately 20% of breast cancers and is associated with more aggressive tumor behavior and a worse prognosis. The HER2/neu protein is a member of the epidermal growth factor receptor family and promotes the growth of cancer cells.

## **Why the Correct Answer is Right**
The correct answer, , implies that HER2/neu overexpression is associated with a worse prognosis but also indicates that targeted therapies are available. Trastuzumab, Pertuzumab, and Ado-trastuzumab emtansine are examples of drugs that specifically target the HER2/neu protein, improving outcomes for patients with HER2-positive breast cancer. The overexpression of HER2/neu makes these cancers more aggressive but also more susceptible to these targeted treatments.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option might suggest that HER2/neu overexpression is associated with a better prognosis, which is incorrect. HER2/neu overexpression is linked to a worse prognosis compared to HER2/neu negative breast cancers.
- **Option B:** This option could imply that HER2/neu overexpression has no impact on prognosis or treatment, which is also incorrect. The overexpression has significant implications for both prognosis and treatment planning.
- **Option C:** If this option suggests that HER2/neu overexpression is not a target for therapy, it would be incorrect. HER2/neu is a specific target for several therapies in breast cancer.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that HER2/neu status is routinely tested in breast cancer patients because it guides treatment decisions, particularly regarding the use of targeted therapies like trastuzumab. Patients with HER2-positive tumors may benefit from these targeted agents, which can significantly improve outcomes.

## **Correct Answer:** D. HER2/neu overexpression is a marker for targeted therapy.